Published in Cancer Weekly, July 12th, 2005
"Proteins in the Bcl-2 family are central regulators of programmed cell death, and members that inhibit apoptosis, such as Bcl-X-L and Bcl-2, are overexpressed in many cancers and contribute to tumor initiation, progression and resistance to therapy. Bcl-X-L expression correlates with chemoresistance of tumor cell lines, and reductions in Bcl-2 increase sensitivity to anticancer drugs and enhance in vivo survival," scientists in the United States reported.
"The development of inhibitors of these proteins as potential anti-cancer therapeutics has been...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.